Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase

Overview

Journal JCO Precis Oncol

Specialty Oncology

Date 2022 Jun 15

PMID 35704797

Authors

Laura Boucai

Federico Salas-Lucia

Gnana P Krishnamoorthy

Eric Sherman

Charles M Rudin

Alexander Drilon

Antonio C Bianco

James A Fagin

Affiliations

Soon will be listed here.

Abstract

Purpose: The development of the selective RET inhibitors selpercatinib and pralsetinib has revolutionized the treatment of metastatic progressive RET-mutant medullary thyroid carcinoma (MTC) and other RET-driven cancers, given their more favorable side-effect profile. The aim of this study is to investigate the mechanisms of selpercatinib-induced thyroid dysfunction in athyreotic patients with RET-mutant MTC and in patients with RET-mutant non-small-cell lung cancer (NSCLC) who had a functional thyroid.

Materials And Methods: Thyroid hormone levels were evaluated in an observational cohort of five athyreotic patients with MTC and 30 patients with NSCLC before and after initiation of selpercatinib. In vitro experiments to identify the mechanism of selpercatinib-induced thyroid dysfunction were conducted in cells expressing endogenous D1, D2, and D3 iodothyronine deiodinases.

Results: Upon initiating treatment with selpercatinib, athyreotic patients developed clinical hypothyroidism with approximately 60% lower T3 levels despite adequate levothyroxine supplementation, whereas in patients with NSCLC, who retain a normal thyroid, selpercatinib resulted in a more attenuated reduction in serum T3, which was dose-dependent. We conducted studies in cells endogenously expressing either D1, D2, or D3, the three iodothyronine deiodinases. Selpercatinib inhibited D2-mediated T3 production in MSTO-211 cells by 50%. A modest repression of D2 mRNA was present in human thyroid cancer TT cells that express RET, but not in the MSTO-211 cells that do not. No effect of the drug was observed on D1 (activating deiodinase) or D3 (inactivating deiodinase). Thus, a nontranscriptional effect of selpercatinib on D2 activity is the most plausible explanation for the low T3 levels.

Conclusion: An off-target effect of selpercatinib on D2-mediated T3 production leads to clinical hypothyroidism, primarily in levothyroxine-treated athyreotic patients. Liothyronine supplementation was needed to achieve normal T3 levels and restore clinical euthyroidism.

Citing Articles

Selpercatinib prior to radioactive iodine for pediatric papillary thyroid carcinoma.

Chiu H, Nowicki T, Livhits M, Wu J, Federman N J Pediatr Endocrinol Metab. 2024; 37(11):1009-1014.

PMID: 39239989 DOI: 10.1515/jpem-2024-0281.

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.

Chen M, Repetto M, Wilhelm C, Drilon A Drugs. 2024; 84(9):1035-1053.

PMID: 38997570 DOI: 10.1007/s40265-024-02040-5.

Tyrosine kinase inhibitor-induced hypothyroidism: mechanism and clinical implications.

Wang Z, Wang H, Bu C, Meng B, Mu Y, Gao S Eur J Clin Pharmacol. 2024; 80(6):827-838.

PMID: 38483545 DOI: 10.1007/s00228-024-03626-4.

Impaired T3 uptake and action in MCT8-deficient cerebral organoids underlie Allan-Herndon-Dudley syndrome.

Salas-Lucia F, Escamilla S, Bianco A, Dumitrescu A, Refetoff S JCI Insight. 2024; 9(7).

PMID: 38376950 PMC: 11128209. DOI: 10.1172/jci.insight.174645.

Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers.

Nardo M, Gouda M, Nelson B, Barreto C, Slade J, Poullard A Cell Rep Med. 2023; 4(12):101332.

PMID: 38118420 PMC: 10772460. DOI: 10.1016/j.xcrm.2023.101332.

References

Kappers M, van Esch J, Smedts F, de Krijger R, Eechoute K, Mathijssen R . Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J Clin Endocrinol Metab. 2011; 96(10):3087-94. DOI: 10.1210/jc.2011-1172. View

Jo S, Kallo I, Bardoczi Z, Arrojo E Drigo R, Zeold A, Liposits Z . Neuronal hypoxia induces Hsp40-mediated nuclear import of type 3 deiodinase as an adaptive mechanism to reduce cellular metabolism. J Neurosci. 2012; 32(25):8491-500. PMC: 3752066. DOI: 10.1523/JNEUROSCI.6514-11.2012. View

Geffner D, Azukizawa M, Hershman J . Propylthiouracil blocks extrathyroidal conversion of thyroxine to triiodothyronine and augments thyrotropin secretion in man. J Clin Invest. 1975; 55(2):224-9. PMC: 301740. DOI: 10.1172/JCI107925. View

Fernandes G, Bocco B, Fonseca T, McAninch E, Jo S, Lartey L . The Foxo1-Inducible Transcriptional Repressor Zfp125 Causes Hepatic Steatosis and Hypercholesterolemia. Cell Rep. 2018; 22(2):523-534. PMC: 6474669. DOI: 10.1016/j.celrep.2017.12.053. View

Guadano-Ferraz A, Obregon M, St Germain D, Bernal J . The type 2 iodothyronine deiodinase is expressed primarily in glial cells in the neonatal rat brain. Proc Natl Acad Sci U S A. 1997; 94(19):10391-6. PMC: 23373. DOI: 10.1073/pnas.94.19.10391. View

Christoffolete M, Ribeiro R, Singru P, Fekete C, da Silva W, Gordon D . Atypical expression of type 2 iodothyronine deiodinase in thyrotrophs explains the thyroxine-mediated pituitary thyrotropin feedback mechanism. Endocrinology. 2006; 147(4):1735-43. DOI: 10.1210/en.2005-1300. View

Rosene M, Wittmann G, Arrojo E Drigo R, Singru P, Lechan R, Bianco A . Inhibition of the type 2 iodothyronine deiodinase underlies the elevated plasma TSH associated with amiodarone treatment. Endocrinology. 2010; 151(12):5961-70. PMC: 2999495. DOI: 10.1210/en.2010-0553. View

Subbiah V, Gainor J, Rahal R, Brubaker J, Kim J, Maynard M . Precision Targeted Therapy with BLU-667 for -Driven Cancers. Cancer Discov. 2018; 8(7):836-849. DOI: 10.1158/2159-8290.CD-18-0338. View

Abdulrahman R, Verloop H, Hoftijzer H, Verburg E, Hovens G, Corssmit E . Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab. 2010; 95(8):3758-62. DOI: 10.1210/jc.2009-2507. View

10.

Fagin J, Wells Jr S . Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med. 2016; 375(23):2307. DOI: 10.1056/NEJMc1613118. View

11.

Bianco A, Salvatore D, Gereben B, Berry M, Larsen P . Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002; 23(1):38-89. DOI: 10.1210/edrv.23.1.0455. View

12.

Bianco A, Anderson G, Forrest D, Galton V, Gereben B, Kim B . American Thyroid Association Guide to investigating thyroid hormone economy and action in rodent and cell models. Thyroid. 2013; 24(1):88-168. PMC: 3887458. DOI: 10.1089/thy.2013.0109. View

13.

Subbiah V, Velcheti V, Tuch B, Ebata K, Busaidy N, Cabanillas M . Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018; 29(8):1869-1876. PMC: 6096733. DOI: 10.1093/annonc/mdy137. View

14.

Braun D, Kim T, le Coutre P, Kohrle J, Hershman J, Schweizer U . Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport. J Clin Endocrinol Metab. 2011; 97(1):E100-5. DOI: 10.1210/jc.2011-1837. View

15.

Tu H, Kim S, Salvatore D, Bartha T, Legradi G, Larsen P . Regional distribution of type 2 thyroxine deiodinase messenger ribonucleic acid in rat hypothalamus and pituitary and its regulation by thyroid hormone. Endocrinology. 1997; 138(8):3359-68. DOI: 10.1210/endo.138.8.5318. View

16.

de Groot J, Zonnenberg B, Plukker J, van der Graaf W, Links T . Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther. 2005; 78(4):433-8. DOI: 10.1016/j.clpt.2005.06.010. View

17.

Curcio C, Baqui M, Salvatore D, Rihn B, Mohr S, Harney J . The human type 2 iodothyronine deiodinase is a selenoprotein highly expressed in a mesothelioma cell line. J Biol Chem. 2001; 276(32):30183-7. DOI: 10.1074/jbc.C100325200. View